BEFORE THE MEDICAL BOARD OF CALIFORNIA DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

Mary Anne Vreeke, M.D.

Physician's & Surgeon's Certificate No. A 78457

Case No. 800-2021-081903

Respondent.

DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on March 15, 2024.

IT IS SO ORDERED: February 16, 2024.

MEDICAL BOARD OF CALIFORNIA

Richard E. Thorp, Chaĭr

Panel B

1 2	ROB BONTA Attorney General of California ALEXANDRA M. ALVAREZ		
3	Supervising Deputy Attorney General JOSEPH F. MCKENNA III		
4	Deputy Attorney General State Bar No. 231195	·	
5	CALIFORNIA DEPARTMENT OF JUSTICE 600 West Broadway, Suite 1800		
6	San Diego, California 92101 P.O. Box 85266		
7	San Diego, California 92186-5266 Telephone: (619) 738-9417 Facsimile: (619) 645-2061		
8	Attorneys for Complainant		
9	PEEOD	, Tritio	
10	BEFORE THE MEDICAL BOARD OF CALIFORNIA		
11.	DEPARTMENT OF CO STATE OF CA		
12			
13	In the Matter of the Accusation Against:	Case No. 800-2021-081903	
14	MARY ANNE VREEKE, M.D. 504 Willow Glen Court	OAH No. 2023090359	
15	Camarillo, California 93012-7841	STIPULATED SETTLEMENT AND DISCIPLINARY ORDER	
16	Physician's and Surgeon's Certificate No. A 78457,	DISCH LINARY ORDER	
17 18	Respondent.		
19	IT IS HEREBY STIPULATED AND AGR	EED by and between the parties to the above-	
20	entitled proceedings that the following matters are	e true:	
21	PARTIES		
22	1. Reji Varghese (Complainant) is the Executive Director of the Medical Board of		
23	California (Board). He brought this action solely in his official capacity and is represented in this		
24	matter by Rob Bonta, Attorney General of the State of California, and by Joseph F. McKenna III,		
25	Deputy Attorney General.		
26	2. Respondent Mary Anne Vreeke, M.D. (Respondent) is represented in this proceeding		
27	by attorney Kevin D. Cauley, Esq., whose address is: 225 South Lake Avenue, Suite 300,		
28	Pasadena, California, 91101.		
		1	
	STIPULATED SETTLEMENT AND DISC	IPLINARY ORDER (Accusation No. 800-2021-081903)	

3. On or about March 27, 2002, the Board issued Physician's and Surgeon's Certificate No. A 78457 to Respondent. The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought in Accusation No. 800-2021-081903, and will expire on February 29, 2024, unless renewed.

JURISDICTION

- 4. On August 16, 2023, Accusation No. 800-2021-081903 was filed before the Board and is currently pending against Respondent. The Accusation and all other statutorily required documents were properly served on Respondent on August 16, 2023. Respondent timely filed her Notice of Defense contesting the Accusation. A true and correct copy of the Accusation is attached hereto as Exhibit A and hereby incorporated by reference as if fully set forth herein.
- 5. On March 10, 2023, a Stipulated Interim Suspension Order (ISO) was issued pursuant to Government Code section 11529 which imposed license restrictions on Respondent's ability to practice medicine. The ISO remains in full force and effect and Respondent is required to fully comply with the terms and conditions of the ISO until issuance of a final decision by the Board on the Accusation or until further order from the Office of Administrative Hearings.

ADVISEMENT AND WAIVERS

- 6. Respondent has carefully read, discussed with counsel, and fully understands the charges and allegations contained in Accusation No. 800-2021-081903. Respondent has also carefully read, discussed with her counsel, and fully understands the effects of this Stipulated Settlement and Disciplinary Order.
- 7. Respondent is fully aware of her legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to confront and cross-examine the witnesses against her; the right to present evidence and to testify on her own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.
- 8. Having the benefit of counsel, Respondent voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

CULPABILITY

9. Respondent admits the truth of each and every charge and allegation contained in Accusation No. 800-2021-081903.

ACKNOWLEDGMENT

10. Respondent acknowledges the Disciplinary Order below, requiring the disclosure of probation pursuant to Business and Professions Code section 2228.1, serves to protect the public interest.

CONTINGENCY

- 11. This stipulation shall be subject to approval by the Board. Respondent understands and agrees that counsel for Complainant and the staff of the Board may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent or her counsel. By signing the stipulation, Respondent understands and agrees that she may not withdraw her agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.
- 12. Respondent agrees that if she ever petitions for early termination or modification of probation, or if an accusation and/or petition to revoke probation is filed against her before the Board, all of the charges and allegations contained in Accusation No. 800-2021-081903 shall be deemed true, correct and fully admitted by Respondent for purposes of any such proceeding or any other licensing proceeding involving Respondent in the State of California.

ADDITIONAL PROVISIONS

- 13. This Stipulated Settlement and Disciplinary Order is intended by the parties herein to be an integrated writing representing the complete, final and exclusive embodiment of the agreements of the parties in the above-entitled matter.
- 14. The parties understand and agree that Portable Document Format (PDF) and facsimile

copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.

15. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or opportunity to be heard by the Respondent, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

1. IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 78457 issued to Respondent MARY ANNE VREEKE, M.D., is revoked. However, the revocation is stayed and Respondent is placed on probation for 10 years from the effective date of the Decision on the following terms and conditions:

2. <u>ACTUAL SUSPENSION</u>.

As part of probation, Respondent is suspended from the practice of medicine for 180 days, beginning the 16th day after the effective date of this Decision.

3. PATIENT DISCLOSURE.

Before a patient's first visit following the effective date of this order and while the Respondent is on probation, the Respondent must provide all patients, or patient's guardian or health care surrogate, with a separate disclosure that includes the Respondent's probation status, the length of the probation, the probation end date, all practice restrictions placed on the Respondent by the Board, the Board's telephone number, and an explanation of how the patient can find further information on the Respondent's probation on the Respondent's profile page on the Board's website. Respondent shall obtain from the patient, or the patient's guardian or health care surrogate, a separate, signed copy of that disclosure. Respondent shall not be required to provide a disclosure if any of the following applies:

- (1) The patient is unconscious or otherwise unable to comprehend the disclosure and sign the copy of the disclosure and a guardian or health care surrogate is unavailable to comprehend the disclosure and sign the copy.
- (2) The visit occurs in an emergency room or an urgent care facility or the visit is unscheduled, including consultations in inpatient facilities.

7

13

14

10

19 20

18

21 22

23

2425

26

2728

- (3) Respondent is not known to the patient until immediately prior to the start of the visit.
- (4) Respondent does not have a direct treatment relationship with the patient.

4. <u>CONTROLLED SUBSTANCES – PARTIAL RESTRICTION</u>.

Respondent shall not order, prescribe, dispense, administer, furnish, or possess any controlled substances as defined by the California Uniform Controlled Substances Act; however, Respondent may order, prescribe, dispense, administer, furnish, or possess any controlled substances as defined by the California Uniform Controlled Substances Act when each of the following 3 conditions are met:

- (1) Respondent must be working in a hospital;
- (2) Respondent must be working in her capacity as an anesthesiologist; and
- (3) Respondent must be engaged in the peri-operative care of patients.

Respondent shall not issue an oral or written recommendation or approval to a patient or a patient's primary caregiver for the possession or cultivation of marijuana for the personal medical purposes of the patient within the meaning of Health and Safety Code section 11362.5. If Respondent forms the medical opinion, after an appropriate prior examination and medical indication, that a patient's medical condition may benefit from the use of marijuana, Respondent shall so inform the patient and shall refer the patient to another physician who, following an appropriate prior examination and medical indication, may independently issue a medically appropriate recommendation or approval for the possession or cultivation of marijuana for the personal medical purposes of the patient within the meaning of Health and Safety Code section 11362.5. In addition, Respondent shall inform the patient or the patient's primary caregiver that Respondent is prohibited from issuing a recommendation or approval for the possession or cultivation of marijuana for the personal medical purposes of the patient and that the patient or the patient's primary caregiver may not rely on Respondent's statements to legally possess or cultivate marijuana for the personal medical purposes of the patient. Respondent shall fully document in the patient's chart that the patient or the patient's primary caregiver was so informed. Nothing in this condition prohibits Respondent from providing the patient or the patient's primary caregiver information about the possible medical benefits resulting from the use of marijuana.

5. <u>CONTROLLED SUBSTANCES – MAINTAIN RECORDS AND ACCESS TO RECORDS AND INVENTORIES.</u>

Respondent shall maintain a record of all controlled substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any recommendation or approval which enables a patient or patient's primary caregiver to possess or cultivate marijuana for the personal medical purposes of the patient within the meaning of Health and Safety Code section 11362.5, during probation, showing all of the following:

- (1) The name and address of the patient;
- (2) The date;
- (3) The character and quantity of controlled substances involved; and
- (4) The indications and diagnosis for which the controlled substances were furnished.

Respondent shall keep these records in a separate file or ledger, in chronological order. All records and any inventories of controlled substances shall be available for immediate inspection and copying on the premises by the Board or its designee at all times during business hours and shall be retained for the entire term of probation.

6. CONTROLLED SUBSTANCES – ABSTAIN FROM USE.

Respondent shall abstain completely from the personal use or possession of controlled substances as defined in the California Uniform Controlled Substances Act, dangerous drugs as defined by Business and Professions Code section 4022, and any drugs requiring a prescription. This prohibition does not apply to medications lawfully prescribed to Respondent by another practitioner for a bona fide illness or condition.

Within 15 calendar days of receiving any lawfully prescribed medications, Respondent shall notify the Board or its designee of the: issuing practitioner's name, address, and telephone number; medication name, strength, and quantity; and issuing pharmacy name, address, and telephone number.

7. <u>ALCOHOL – ABSTAIN FROM USE</u>.

Respondent shall abstain completely from the use of products or beverages containing alcohol.

8. PRESCRIBING PRACTICES COURSE.

Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a course in prescribing practices approved in advance by the Board or its designee. Respondent shall provide the approved course provider with any information and documents that the approved course provider may deem pertinent. Respondent shall participate in and successfully complete the classroom component of the course not later than 6 months after Respondent's initial enrollment. Respondent shall successfully complete any other component of the course within 1 year of enrollment. The prescribing practices course shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

A prescribing practices course taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the course would have been approved by the Board or its designee had the course been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the course, or not later than 15 calendar days after the effective date of the Decision, whichever is later.

9. <u>MEDICAL RECORD KEEPING COURSE</u>.

Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a course in medical record keeping approved in advance by the Board or its designee. Respondent shall provide the approved course provider with any information and documents that the approved course provider may deem pertinent. Respondent shall participate in and successfully complete the classroom component of the course not later than 6 months after Respondent's initial enrollment. Respondent shall successfully complete any other component of the course within 1 year of enrollment. The medical record keeping course shall be at Respondent's expense and shall be in addition to the CME requirements for renewal of licensure.

A medical record keeping course taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board

 or its designee, be accepted towards the fulfillment of this condition if the course would have been approved by the Board or its designee had the course been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the course, or not later than 15 calendar days after the effective date of the Decision, whichever is later.

10. PROFESSIONALISM PROGRAM (ETHICS COURSE).

Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a professionalism program, that meets the requirements of Title 16, California Code of Regulations (CCR) section 1358.1. Respondent shall participate in and successfully complete that program. Respondent shall provide any information and documents that the program may deem pertinent. Respondent shall successfully complete the classroom component of the program not later than 6 months after Respondent's initial enrollment, and the longitudinal component of the program not later than the time specified by the program, but no later than 1 year after attending the classroom component. The professionalism program shall be at Respondent's expense and shall be in addition to the CME requirements for renewal of licensure.

A professionalism program taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the program would have been approved by the Board or its designee had the program been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the program or not later than 15 calendar days after the effective date of the Decision, whichever is later.

11. <u>PSYCHIATRIC EVALUATION</u>.

Within 30 calendar days of the effective date of this Decision, and on whatever periodic basis thereafter may be required by the Board or its designee, Respondent shall undergo and complete a psychiatric evaluation (and psychological testing, if deemed necessary) by a Board-

appointed board certified psychiatrist, who shall consider any information provided by the Board or designee and any other information the psychiatrist deems relevant, and shall furnish a written evaluation report to the Board or its designee. Psychiatric evaluations conducted prior to the effective date of the Decision shall not be accepted towards the fulfillment of this requirement. Respondent shall pay the cost of all psychiatric evaluations and psychological testing.

Respondent shall comply with all restrictions or conditions recommended by the evaluating psychiatrist within 15 calendar days after being notified by the Board or its designee.

12. PSYCHOTHERAPY.

Within 60 calendar days of the effective date of this Decision, Respondent shall submit to the Board or its designee for prior approval the name and qualifications of a California-licensed board certified psychiatrist or a licensed psychologist who has a doctoral degree in psychology and at least 5 years of postgraduate experience in the diagnosis and treatment of emotional and mental disorders. Upon approval, Respondent shall undergo and continue psychotherapy treatment, including any modifications to the frequency of psychotherapy, until the Board or its designee deems that no further psychotherapy is necessary.

The psychotherapist shall consider any information provided by the Board or its designee and any other information the psychotherapist deems relevant and shall furnish a written evaluation report to the Board or its designee. Respondent shall cooperate in providing the psychotherapist with any information and documents that the psychotherapist may deem pertinent.

Respondent shall have the treating psychotherapist submit quarterly status reports to the Board or its designee. The Board or its designee may require Respondent to undergo psychiatric evaluations by a Board-appointed board certified psychiatrist. If, prior to the completion of probation, Respondent is found to be mentally unfit to resume the practice of medicine without restrictions, the Board shall retain continuing jurisdiction over Respondent's license and the period of probation shall be extended until the Board determines that Respondent is mentally fit to resume the practice of medicine without restrictions.

Respondent shall pay the cost of all psychotherapy and psychiatric evaluations.

13. <u>MEDICAL EVALUATION AND TREATMENT</u>.

Within 30 calendar days of the effective date of this Decision, and on a periodic basis thereafter as may be required by the Board or its designee, Respondent shall undergo a medical evaluation by a Board-appointed physician who shall consider any information provided by the Board or designee and any other information the evaluating physician deems relevant and shall furnish a medical report to the Board or its designee. Respondent shall provide the evaluating physician with any information and documentation that the evaluating physician may deem pertinent.

Following the evaluation, Respondent shall comply with all restrictions or conditions recommended by the evaluating physician within 15 calendar days after being notified by the Board or its designee. If Respondent is required by the Board or its designee to undergo medical treatment, Respondent shall within 30 calendar days of the requirement notice, submit to the Board or its designee for prior approval the name and qualifications of a California licensed treating physician of Respondent's choice. Upon approval of the treating physician, Respondent shall within 15 calendar days undertake medical treatment and shall continue such treatment until further notice from the Board or its designee.

The treating physician shall consider any information provided by the Board or its designee or any other information the treating physician may deem pertinent prior to commencement of treatment. Respondent shall have the treating physician submit quarterly reports to the Board or its designee indicating whether or not the Respondent is capable of practicing medicine safely. Respondent shall provide the Board or its designee with any and all medical records pertaining to treatment that the Board or its designee deems necessary.

If, prior to the completion of probation, Respondent is found to be physically incapable of resuming the practice of medicine without restrictions, the Board shall retain continuing jurisdiction over Respondent's license and the period of probation shall be extended until the Board determines that Respondent is physically capable of resuming the practice of medicine without restrictions. Respondent shall pay the cost of the medical evaluation(s) and treatment.

14. MONITORING - PRACTICE.

Within 30 calendar days of the effective date of this Decision, Respondent shall submit to the Board or its designee for prior approval as a practice monitor, the name and qualifications of one or more licensed physicians and surgeons whose licenses are valid and in good standing, and who are preferably American Board of Medical Specialties (ABMS) certified. A monitor shall have no prior or current business or personal relationship with Respondent, or other relationship that could reasonably be expected to compromise the ability of the monitor to render fair and unbiased reports to the Board, including but not limited to any form of bartering. Unless prior approval is granted by the Board or its designee, the monitor shall be in Respondent's field of practice, and must agree to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

The Board or its designee shall provide the approved monitor with copies of the Decision and Disciplinary Order and Accusation No. 800-2021-081903, and a proposed monitoring plan. Within 15 calendar days of receipt of the Decision and Disciplinary Order and Accusation, and proposed monitoring plan, the monitor shall submit a signed statement that the monitor has read the Decision and Disciplinary Order and the Accusation, fully understands the role of a monitor, and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees with the proposed monitoring plan, the monitor shall submit a revised monitoring plan with the signed statement for approval by the Board or its designee.

Within 60 calendar days of the effective date of this Decision, and continuing throughout probation, Respondent's practice shall be monitored by the approved monitor. Respondent shall make all records available for immediate inspection and copying on the premises by the monitor at all times during business hours and shall retain the records for the entire term of probation.

If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective date of this Decision, Respondent shall receive a notification from the Board or its designee to cease the practice of medicine within 3 calendar days after being so notified. Respondent shall cease the practice of medicine until a monitor is approved to provide monitoring responsibility.

The monitor shall submit a quarterly written report to the Board or its designee which includes an evaluation of Respondent's performance, indicating whether Respondent's practices are within the standards of practice of medicine and whether Respondent is practicing medicine safely. It shall be the sole responsibility of Respondent to ensure that the monitor submits the quarterly written reports to the Board or its designee within 10 calendar days after the end of the preceding quarter.

If the monitor resigns or is no longer available, Respondent shall, within 5 calendar days of such resignation or unavailability, submit to the Board or its designee, for prior approval, the name and qualifications of a replacement monitor who will be assuming that responsibility within 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a notification from the Board or its designee to cease the practice of medicine within 3 calendar days after being so notified. Respondent shall cease the practice of medicine until a replacement monitor is approved and assumes monitoring responsibility.

In lieu of a monitor, Respondent may participate in a professional enhancement program approved in advance by the Board or its designee that includes, at minimum, quarterly chart review, semi-annual practice assessment, and semi-annual review of professional growth and education. Respondent shall participate in the professional enhancement program at Respondent's expense during the term of probation.

15. SOLO PRACTICE PROHIBITION.

Respondent is prohibited from engaging in the solo practice of medicine. Prohibited solo practice includes, but is not limited to, a practice where:

- (1) Respondent merely shares office space with another physician but is not affiliated for purposes of providing patient care, or
 - (2) Respondent is the sole physician practitioner at that location.

If Respondent fails to establish a practice with another physician or secure employment in an appropriate practice setting within 60 calendar days of the effective date of this Decision, Respondent shall receive a notification from the Board or its designee to cease the practice of

medicine within 3 calendar days after being so notified. The Respondent shall not resume practice until an appropriate practice setting is established.

If, during the course of the probation, the Respondent's practice setting changes and the Respondent is no longer practicing in a setting in compliance with this Decision and Disciplinary Order, the Respondent shall notify the Board or its designee within 5 calendar days of the practice setting change. If Respondent fails to establish a practice with another physician or secure employment in an appropriate practice setting within 60 calendar days of the practice setting change, Respondent shall receive a notification from the Board or its designee to cease the practice of medicine within 3 calendar days after being so notified. The Respondent shall not resume practice until an appropriate practice setting is established.

16. CLINICAL DIAGNOSTIC EVALUATIONS AND REPORTS.

Within 30 calendar days of the effective date of this Decision, and on whatever periodic basis thereafter as may be required by the Board or its designee, Respondent shall undergo and complete a clinical diagnostic evaluation, including any and all testing deemed necessary, by a Board-appointed board certified physician and surgeon. The examiner shall consider any information provided by the Board or its designee and any other information he or she deems relevant, and shall furnish a written evaluation report to the Board or its designee.

The clinical diagnostic evaluation shall be conducted by a licensed physician and surgeon who holds a valid, unrestricted license, has 3 years' experience in providing evaluations of physicians and surgeons with substance abuse disorders, and is approved by the Board or its designee. The clinical diagnostic evaluation shall be conducted in accordance with acceptable professional standards for conducting substance abuse clinical diagnostic evaluations. The evaluator shall not have a current or former financial, personal, or business relationship with Respondent within the last 5 years. The evaluator shall provide an objective, unbiased, and independent evaluation. The clinical diagnostic evaluation report shall set forth, in the evaluator's opinion, whether Respondent has a substance abuse problem, whether Respondent is a threat to herself or others, and recommendations for substance abuse treatment, practice restrictions, or other recommendations related to Respondent's rehabilitation and ability to practice safely. If the

evaluator determines during the evaluation process that Respondent is a threat to herself or others, the evaluator shall notify the Board within 24 hours of such a determination.

In formulating his or her opinion as to whether Respondent is safe to return to either parttime or full-time practice and what restrictions or recommendations should be imposed, including
participation in an inpatient or outpatient treatment program, the evaluator shall consider the
following factors: Respondent's license type; Respondent's history; Respondent's documented
length of sobriety (i.e., length of time that has elapsed since Respondent's last substance use);
Respondent's scope and pattern of substance abuse; Respondent's treatment history, medical
history and current medical condition; the nature, duration and severity of Respondent's
substance abuse problem or problems; and whether Respondent is a threat to herself or the public.

For all clinical diagnostic evaluations, a final written report shall be provided to the Board no later than 10 days from the date the evaluator is assigned the matter. If the evaluator requests additional information or time to complete the evaluation and report, an extension may be granted, but shall not exceed 30 days from the date the evaluator was originally assigned the matter.

The Board shall review the clinical diagnostic evaluation report within 5 business days of receipt to determine whether Respondent is safe to return to either part-time or full-time practice and what restrictions or recommendations shall be imposed on Respondent based on the recommendations made by the evaluator. Respondent shall not be returned to practice until she has at least 30 days of negative biological fluid tests or biological fluid tests indicating that she has not used, consumed, ingested, or administered to herself a prohibited substance, as defined in section 1361.51, subdivision (e), of Title 16 of the California Code of Regulations.

Clinical diagnostic evaluations conducted prior to the effective date of this Decision shall not be accepted towards the fulfillment of this requirement. The cost of the clinical diagnostic evaluation, including any and all testing deemed necessary by the examiner, the Board or its designee, shall be borne by the licensee.

Respondent shall not engage in the practice of medicine until notified by the Board or its designee that she is fit to practice medicine safely. The period of time that Respondent is not

practicing medicine shall not be counted toward completion of the term of probation. Respondent shall undergo biological fluid testing as required in this Decision at least 2 times per week while awaiting the notification from the Board if she is fit to practice medicine safely.

Respondent shall comply with all restrictions or conditions recommended by the examiner conducting the clinical diagnostic evaluation within 15 calendar days after being notified by the Board or its designee.

17. NOTICE OF EMPLOYER OR SUPERVISOR INFORMATION.

Within 7 days of the effective date of this Decision, Respondent shall provide the Board the names, physical addresses, mailing addresses, and telephone numbers of any and all employers and supervisors. Respondent shall also provide specific, written consent for the Board, Respondent's worksite monitor, and Respondent's employers and supervisors to communicate regarding Respondent's work status, performance, and monitoring.

For purposes of this section, "supervisors" shall include the Chief of Staff and Health or Well Being Committee Chair, or equivalent, if applicable, when the Respondent has medical staff privileges.

18. <u>BIOLOGICAL FLUID TESTING</u>.

Respondent shall immediately submit to biological fluid testing, at Respondent's expense, upon request of the Board or its designee. "Biological fluid testing" may include, but is not limited to, urine, blood, breathalyzer, hair follicle testing, or similar drug screening approved by the Board or its designee. Respondent shall make daily contact with the Board or its designee to determine whether biological fluid testing is required. Respondent shall be tested on the date of the notification as directed by the Board or its designee. The Board may order a Respondent to undergo a biological fluid test on any day, at any time, including weekends and holidays. Except when testing on a specific date as ordered by the Board or its designee, the scheduling of biological fluid testing shall be done on a random basis. The cost of biological fluid testing shall be borne by the Respondent.

During the first year of probation, Respondent shall be subject to 52 to 104 random tests.

During the second year of probation and for the duration of the probationary term, up to 5 years,

Respondent shall be subject to 36 to 104 random tests per year. Only if there has been no positive biological fluid tests in the previous 5 consecutive years of probation, may testing be reduced to 1 time per month. Nothing precludes the Board from increasing the number of random tests to the first-year level of frequency for any reason.

Prior to practicing medicine, Respondent shall contract with a laboratory or service, approved in advance by the Board or its designee, that will conduct random, unannounced, observed, biological fluid testing and meets all of the following standards:

- (a) Its specimen collectors are either certified by the Drug and Alcohol Testing Industry
 Association or have completed the training required to serve as a collector for the United
 States Department of Transportation.
- (b) Its specimen collectors conform to the current United States Department of Transportation Specimen Collection Guidelines.
- (c) Its testing locations comply with the Urine Specimen Collection Guidelines published by the United States Department of Transportation without regard to type of test administered.
- (d) Its specimen collectors observe the collection of testing specimens.
- (e) Its laboratories are certified and accredited by the United States Department of Health and Human Services.
- (f) Its testing locations shall submit a specimen to a laboratory within 1 business day of receipt and all specimens collected shall be handled pursuant to chain of custody procedures. The laboratory shall process and analyze the specimens and provide legally defensible test results to the Board within 7 business days of receipt of the specimen. The Board will be notified of non-negative results within 1 business day and will be notified of negative test results within 7 business days.
- (g) Its testing locations possess all the materials, equipment, and technical expertise necessary in order to test Respondent on any day of the week.
- (h) Its testing locations are able to scientifically test for urine, blood, and hair specimens for the detection of alcohol and illegal and controlled substances.
- (i) It maintains testing sites located throughout California.

- (j) It maintains an automated 24-hour toll-free telephone system and/or a secure on-line computer database that allows the Respondent to check in daily for testing.
- (k) It maintains a secure, HIPAA-compliant website or computer system that allows staff access to drug test results and compliance reporting information that is available 24 hours a day.
- (l) It employs or contracts with toxicologists that are licensed physicians and have knowledge of substance abuse disorders and the appropriate medical training to interpret and evaluate laboratory biological fluid test results, medical histories, and any other information relevant to biomedical information.
- (m) It will not consider a toxicology screen to be negative if a positive result is obtained while practicing, even if the Respondent holds a valid prescription for the substance.

Prior to changing testing locations for any reason, including during vacation or other travel, alternative testing locations must be approved by the Board and meet the requirements above.

The contract shall require that the laboratory directly notify the Board or its designee of non-negative results within 1 business day and negative test results within 7 business days of the results becoming available. Respondent shall maintain this laboratory or service contract during the period of probation.

A certified copy of any laboratory test result may be received in evidence in any proceedings between the Board and Respondent.

If a biological fluid test result indicates Respondent has used, consumed, ingested, or administered to herself a prohibited substance, the Board shall order Respondent to cease practice and instruct Respondent to leave any place of work where Respondent is practicing medicine or providing medical services. The Board shall immediately notify all of Respondent's employers, supervisors and work monitors, if any, that Respondent may not practice medicine or provide medical services while the cease-practice order is in effect.

A biological fluid test will not be considered negative if a positive result is obtained while practicing, even if the practitioner holds a valid prescription for the substance. If no prohibited substance use exists, the Board shall lift the cease-practice order within 1 business day.

After the issuance of a cease-practice order, the Board shall determine whether the positive biological fluid test is in fact evidence of prohibited substance use by consulting with the specimen collector and the laboratory, communicating with the licensee, her treating physician(s), other health care provider, or group facilitator, as applicable.

For purposes of this condition, the terms "biological fluid testing" and "testing" mean the acquisition and chemical analysis of a Respondent's urine, blood, breath, or hair.

For purposes of this condition, the term "prohibited substance" means an illegal drug, a lawful drug not prescribed or ordered by an appropriately licensed health care provider for use by Respondent and approved by the Board, alcohol, or any other substance the Respondent has been instructed by the Board not to use, consume, ingest, or administer to herself.

If the Board confirms that a positive biological fluid test is evidence of use of a prohibited substance, Respondent has committed a major violation, as defined in section 1361.52(a), and the Board shall impose any or all of the consequences set forth in section 1361.52(b), in addition to any other terms or conditions the Board determines are necessary for public protection or to enhance Respondent's rehabilitation.

19. SUBSTANCE ABUSE SUPPORT GROUP MEETINGS.

Within 30 days of the effective date of this Decision, Respondent shall submit to the Board or its designee, for its prior approval, the name of a substance abuse support group which she shall attend for the duration of probation. Respondent shall attend substance abuse support group meetings at least once per week, or as ordered by the Board or its designee. Respondent shall pay all substance abuse support group meeting costs.

The facilitator of the substance abuse support group meeting shall have a minimum of 3 years' experience in the treatment and rehabilitation of substance abuse, and shall be licensed or certified by the state or nationally certified organizations. The facilitator shall not have a current or former financial, personal, or business relationship with Respondent within the last 5 years. Respondent's previous participation in a substance abuse group support meeting led by the same facilitator does not constitute a prohibited current or former financial, personal, or business relationship.

The facilitator shall provide a signed document to the Board or its designee showing Respondent's name, the group name, the date and location of the meeting, Respondent's attendance, and Respondent's level of participation and progress. The facilitator shall report any unexcused absence by Respondent from any substance abuse support group meeting to the Board, or its designee, within 24 hours of the unexcused absence.

20. WORKSITE MONITOR FOR SUBSTANCE-ABUSING LICENSEE.

Within 30 calendar days of the effective date of this Decision, Respondent shall submit to the Board or its designee for prior approval as a worksite monitor, the name and qualifications of one or more licensed physician and surgeon, other licensed health care professional if no physician and surgeon is available, or, as approved by the Board or its designee, a person in a position of authority who is capable of monitoring the Respondent at work.

The worksite monitor shall not have a current or former financial, personal, or familial relationship with Respondent, or any other relationship that could reasonably be expected to compromise the ability of the monitor to render impartial and unbiased reports to the Board or its designee. If it is impractical for anyone but Respondent's employer to serve as the worksite monitor, this requirement may be waived by the Board or its designee, however, under no circumstances shall Respondent's worksite monitor be an employee or supervisee of the licensee.

The worksite monitor shall have an active unrestricted license with no disciplinary action within the last 5 years, and shall sign an affirmation that he or she has reviewed the terms and conditions of Respondent's disciplinary order and agrees to monitor Respondent as set forth by the Board or its designee.

Respondent shall pay all worksite monitoring costs.

The worksite monitor shall have face-to-face contact with Respondent in the work environment on as frequent a basis as determined by the Board or its designee, but not less than once per week; interview other staff in the office regarding Respondent's behavior, if requested by the Board or its designee; and review Respondent's work attendance.

The worksite monitor shall verbally report any suspected substance abuse to the Board and Respondent's employer or supervisor within 1 business day of occurrence. If the suspected

substance abuse does not occur during the Board's normal business hours, the verbal report shall be made to the Board or its designee within 1 hour of the next business day. A written report that includes the date, time, and location of the suspected abuse; Respondent's actions; and any other information deemed important by the worksite monitor shall be submitted to the Board or its designee within 48 hours of the occurrence.

The worksite monitor shall complete and submit a written report monthly or as directed by the Board or its designee which shall include the following:

- (1) Respondent's name and Physician's and Surgeon's Certificate number;
- (2) The worksite monitor's name and signature;
- (3) The worksite monitor's license number, if applicable;
- (4) The location or location(s) of the worksite;
- (5) The dates Respondent had face-to-face contact with the worksite monitor;
- (6) The names of worksite staff interviewed, if applicable;
- (7) A report of Respondent's work attendance;
- (8) Any change in Respondent's behavior and/or personal habits; and
- (9) Any indicators that can lead to suspected substance abuse by Respondent.

Respondent shall complete any required consent forms and execute agreements with the approved worksite monitor and the Board, or its designee, authorizing the Board, or its designee, and worksite monitor to exchange information.

If the worksite monitor resigns or is no longer available, Respondent shall, within 5 calendar days of such resignation or unavailability, submit to the Board or its designee, for prior approval, the name and qualifications of a replacement monitor who will be assuming that responsibility within 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a notification from the Board or its designee to cease the practice of medicine within 3 calendar days after being so notified. Respondent shall cease the practice of medicine until a replacement monitor is approved and assumes monitoring responsibility.

21. <u>VIOLATION OF PROBATION CONDITION FOR SUBSTANCE ABUSING</u> <u>LICENSEES</u>.

Failure to fully comply with any term or condition of probation is a violation of probation.

- A. If Respondent commits a major violation of probation as defined by section 1361.52, subdivision (a), of Title 16 of the California Code of Regulations, the Board shall take one or more of the following actions:
- (1) Issue an immediate cease-practice order and order Respondent to undergo a clinical diagnostic evaluation to be conducted in accordance with section 1361.5, subdivision (c)(1), of Title 16 of the California Code of Regulations, at Respondent's expense. The cease-practice order issued by the Board or its designee shall state that Respondent must test negative for at least a month of continuous biological fluid testing before being allowed to resume practice. For purposes of determining the length of time a Respondent must test negative while undergoing continuous biological fluid testing following issuance of a cease-practice order, a month is defined as 30 calendar days. Respondent may not resume the practice of medicine until notified in writing by the Board or its designee that she may do so;
 - (2) Increase the frequency of biological fluid testing; and/or
- (3) Refer Respondent for further disciplinary action, such as suspension, revocation, or other action as determined by the Board or its designee.
- B. If Respondent commits a minor violation of probation as defined by section 1361.52, subdivision (c), of Title 16 of the California Code of Regulations, the Board shall take one or more of the following actions:
 - (1) Issue a cease-practice order;
 - (2) Order practice limitations;
 - (3) Order or increase supervision of Respondent;
 - (4) Order increased documentation;
 - (5) Issue a citation and fine, or a warning letter;
- (6) Order Respondent to undergo a clinical diagnostic evaluation to be conducted in

accordance with section 1361.5, subdivision (c)(1), of Title 16 of the California Code of Regulations, at Respondent's expense; and/or

- (7) Take any other action as determined by the Board or its designee.
- C. Nothing in this Decision shall be considered a limitation on the Board's authority to revoke Respondent's probation if she has violated any term or condition of probation. If Respondent violates probation in any respect, the Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation, or an Interim Suspension Order is filed against Respondent during probation, the Board shall have continuing jurisdiction until the matter is final, and the period of probation shall be extended until the matter is final.

22. NOTIFICATION.

Within 7 days of the effective date of this Decision, the Respondent shall provide true and correct copies of this Decision and Disciplinary Order and Accusation No. 800-2021-081903 to the Chief of Staff or the Chief Executive Officer at every hospital where privileges or membership are extended to Respondent, at any other facility where Respondent engages in the practice of medicine, including all physician and locum tenens registries or other similar agencies, and to the Chief Executive Officer at every insurance carrier which extends malpractice insurance coverage to Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15 calendar days.

This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

23. <u>SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE</u>
NURSES.

During probation, Respondent is prohibited from supervising physician assistants and advanced practice nurses.

24. OBEY ALL LAWS.

Respondent shall obey all federal, state and local laws, all rules governing the practice of medicine in California and remain in full compliance with any court ordered criminal probation, payments, and other orders.

25. INVESTIGATION/ENFORCEMENT COST RECOVERY.

Respondent is hereby ordered to reimburse the Board its costs of investigation and enforcement, including legal review and expert review, as applicable, fifty-five thousand forty dollars and seventy-five cents (\$55,040.75). Costs shall be payable to the Board. Failure to pay such costs shall be considered a violation of this agreement and shall be deemed an act of unprofessional conduct and a separate and distinct basis for discipline.

Any requests for a payment plan shall be submitted in writing by Respondent to the Board.

The filing of bankruptcy by Respondent shall not relieve Respondent of the responsibility to repay investigation and enforcement costs, including expert review costs (if applicable).

26. QUARTERLY DECLARATIONS.

Respondent shall submit quarterly declarations under penalty of perjury on forms provided by the Board, stating whether there has been compliance with all the conditions of probation.

Respondent shall submit quarterly declarations not later than 10 calendar days after the end of the preceding quarter.

27. GENERAL PROBATION REQUIREMENTS.

Compliance with Probation Unit

Respondent shall comply with the Board's probation unit.

Address Changes

Respondent shall, at all times, keep the Board informed of Respondent's business and residence addresses, email address (if available), and telephone number. Changes of such addresses shall be immediately communicated in writing to the Board or its designee. Under no circumstances shall a post office box serve as an address of record, except as allowed by Business and Professions Code section 2021, subdivision (b).

Place of Practice

Respondent shall not engage in the practice of medicine in Respondent's or patient's place of residence, unless the patient resides in a skilled nursing facility or other similar licensed facility.

License Renewal

Respondent shall maintain a current and renewed California physician's and surgeon's license.

Travel or Residence Outside California

Respondent shall immediately inform the Board or its designee, in writing, of travel to any areas outside the jurisdiction of California which lasts, or is contemplated to last, more than 30 calendar days.

In the event Respondent should leave the State of California to reside or to practice Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of departure and return.

28. INTERVIEW WITH THE BOARD OR ITS DESIGNEE.

Respondent shall be available in person upon request for interviews either at Respondent's place of business or at the probation unit office, with or without prior notice throughout the term of probation.

29. NON-PRACTICE WHILE ON PROBATION.

Respondent shall notify the Board or its designee in writing within 15 calendar days of any periods of non-practice lasting more than 30 calendar days and within 15 calendar days of her return to practice. Non-practice is defined as any period of time Respondent is not practicing medicine as defined in Bus. and Prof. Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct patient care, clinical activity, teaching, or other activity as approved by the Board. If Respondent resides in California and is considered to be in non-practice, she shall comply with all terms and conditions of probation. All time spent in an intensive training program which has been approved by the Board or its designee shall not be considered non-practice and does not relieve her from complying with all the terms and conditions of probation. Practicing medicine in another state of the United States or Federal jurisdiction while on probation with the medical licensing authority of that state or jurisdiction shall not be considered non-practice. A Board-ordered suspension of practice shall not be considered as a period of non-practice.

 In the event Respondent's period of non-practice while on probation exceeds 18 calendar months, Respondent shall successfully complete the Federation of State Medical Boards' Special Purpose Examination, or, at the Board's discretion, a clinical competence assessment program that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

Respondent's period of non-practice while on probation shall not exceed 2 years.

Periods of non-practice will not apply to the reduction of the probationary term.

Periods of non-practice for a Respondent residing outside of California will relieve
Respondent of the responsibility to comply with the probationary terms and conditions with the
exception of this condition and the following terms and conditions of probation: Obey All Laws;
General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or
Controlled Substances; and Biological Fluid Testing.

30. COMPLETION OF PROBATION.

Respondent shall comply with all financial obligations (e.g., probation costs) not later than 120 calendar days prior to the completion of probation. This term does not include cost recovery, which is due within 30 calendar days of the effective date of the Order, or by a payment plan approved by the Medical Board and timely satisfied. Upon successful completion of probation, Respondent's certificate shall be fully restored.

31. VIOLATION OF PROBATION.

Failure to fully comply with any term or condition of probation is a violation of probation. If Respondent violates probation in any respect, the Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation, or an Interim Suspension Order is filed against Respondent during probation, the Board shall have continuing jurisdiction until the matter is final, and the period of probation shall be extended until the matter is final.

32. <u>LICENSE SURRENDER</u>.

Following the effective date of this Decision, if Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy the terms and conditions of

probation, Respondent may request to surrender her license. The Board reserves the right to evaluate Respondent's request and to exercise its discretion in determining whether or not to grant the request, or to take any other action deemed appropriate and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its designee and Respondent shall no longer practice medicine. Respondent will no longer be subject to the terms and conditions of probation. If Respondent re-applies for a medical license, the application shall be treated as a petition for reinstatement of a revoked certificate.

PROBATION MONITORING COSTS.

Respondent shall pay the costs associated with probation monitoring each and every year of probation, as designated by the Board, which may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of California and delivered to the Board or its designee no later than January 31 of each calendar year.

34. FUTURE ADMISSIONS CLAUSE.

If Respondent should ever apply or reapply for a new license or certification, or petition for reinstatement of a license, by any other health care licensing action agency in the State of California, all of the charges and allegations contained in Accusation No. 800-2021-081903 shall be deemed to be true, correct, and fully admitted by Respondent for the purpose of any Statement of Issues or any other proceeding seeking to deny or restrict license.

ACCEPTANCE

I have earefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney. Kevin D. Cauley, Esq. I fully understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: 1-05-2024 // MARY ANNE VREEKE, M.D.
Respondent

I have read and fully discussed with Respondent Mary Anne Vreeke, M.D., the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: January 5, 2024

- 2

3

. 4

15

6

8

10

11

12

13

14

15

16

1.7

18

-19

20

.21

22

23

24

25

26

27

. 28

KEVIN D. CAULEY, ESP.
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: Vanuary 5, 2024

Respectfully submitted.

ROB BONTA
Attorney General of California
ALEXANDRA M. ALVAREZ
Supervising Deputy Attorney General

Joshm F. McKenna III Deputy Attorney General Attorneys for Complainant

1.A2023600160 84313222.docx

.1	ROB BONTA		
2	Attorney General of California ALEXANDRA M. ALVAREZ		
3	Supervising Deputy Attorney General JOSEPH F. MCKENNA III		
4	Deputy Attorney General State Bar No. 231195		
5	California Department of Justice 600 West Broadway, Suite 1800		
6	San Diego, California 92101 P.O. Box 85266		
7	San Diego, California 92186-5266 Telephone: (619) 738-9417		
8	Facsimile: (619) 645-2061 Attorneys for Complainant	1	
9			
10	BEFORE THE MEDICAL BOARD OF CALIFORNIA		
11	DEPARTMENT OF CONSUMER AFFAIRS		
12	STATE OF CA	LIFUKNIA	
13			
14	In the Matter of the Accusation Against:	Case No. 800-2021-081903	
15	MARY ANNE VREEKE, M.D. 504 Willow Glen Court	ACCUSATION	
16	Camarillo, California 93012		
17	Physician's and Surgeon's Certificate No. A 78457,		
18	Respondent.		
19			
20		TEC	
21	PART	. _	
22	1. Reji Varghese (Complainant) brings this Accusation solely in his official capacity as		
23	the Executive Director of the Medical Board of California, Department of Consumer Affairs		
24	(Board).	d issued Physician's and Surgeon's Certificate	
25	2. On or about March 27, 2002, the Board issued Physician's and Surgeon's Certificate		
26	No. A 78457 to Mary Anne Vreeke, M.D. (Respondent). The Physician's and Surgeon's		
27	Certificate was in full force and effect at all times relevant to the charges brought herein and will		
28	expire on February 29, 2024, unless renewed.		
	(MARY ANNE VREEKE, M.D.) ACCUSATION NO. 800-2021-081903		

PROCEDURAL HISTORY REGARDING INTERIM ORDER

3. On March 14, 2023, pursuant to the provisions of California Government Code section 11529, an administrative law judge issued an Interim Order Imposing License Restrictions (Interim Order) restricting Physician's and Surgeon's Certificate No. A 78457, and requiring Respondent to comply with multiple license restrictions including: abstain from use of controlled substances; abstain from use of alcohol; biological fluid testing; substance abuse support group meetings; psychotherapy; and have a worksite monitor for substance-abusing licensee. The Interim Order will remain in effect, pending a full determination whether Respondent has violated the Medical Practice Act or upon further order by the Medical Board in this matter. As part of the "Stipulation of the Parties re Interim Order Imposing License Restrictions and Order," Respondent agreed to and has waived all of her rights under California Government Code section 11529, subsections (f) and (g), including, waived the right to have the Interim Order dissolved if an Accusation was not filed within 30 days of the date that the Interim Order was issued.

JURISDICTION

- 4. This Accusation is brought before the Board under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.
 - 5. Section 2220 of the Code states, in relevant part:

Except as otherwise provided by law, the board may take action against all persons guilty of violating this chapter. The board shall enforce and administer this article as to physician and surgeon certificate holders, including those who hold certificates that do not permit them to practice medicine, such as, but not limited to, retired, inactive, or disabled status certificate holders, and the board shall have all the powers granted in this chapter for these purposes ...

STATUTORY PROVISIONS

- 6. Section 2227 of the Code states:
- (a) A licensee whose matter has been heard by an administrative law judge of the Medical Quality Hearing Panel as designated in Section 11371 of the Government Code, or whose default has been entered, and who is found guilty, or who has entered into a stipulation for disciplinary action with the board, may, in accordance with the provisions of this chapter:
 - (1) Have his or her license revoked upon order of the board.
- (2) Have his or her right to practice suspended for a period not to exceed one year upon order of the board.

...

9. Unprofessional conduct under Business and Professions Code section 2234 is conduct which breaches the rules or ethical code of the medical profession, or conduct which is unbecoming to a member in good standing of the medical profession, and which demonstrates an unfitness to practice medicine. (*Shea v. Board of Medical Examiners* (1978) 81 Cal.App.3d 564, 575.)

10. Section 2238 of the Code states:

A violation of any federal statute or federal regulation or any of the statutes or regulations of this state regulating dangerous drugs or controlled substances constitutes unprofessional conduct.

11. Section 2239 of the Code states, in relevant part:

(a) The use or prescribing for or administering to himself or herself, of any controlled substance; or the use of any of the dangerous drugs specified in Section 4022, or of alcoholic beverages, to the extent, or in such a manner as to be dangerous or injurious to the licensee, or to any other person or to the public, or to the extent that such use impairs the ability of the licensee to practice medicine safely ... constitutes unprofessional conduct. ...

12. Section 2280 of the Code states:

No licensee shall practice medicine while under the influence of any narcotic drug or alcohol to such an extent as to impair his or her ability to conduct the practice of medicine with safety to the public and his or her patients. Violation of this section constitutes unprofessional conduct and is a misdemeanor.

13. Section 11170 of the Health and Safety Code states:

No person shall prescribe, administer, or furnish a controlled substance for himself.

14. Section 11171 of the Health and Safety Code states:

No person shall prescribe, administer, or furnish a controlled substance except under the conditions and in the manner provided by this division.

15. Section 11173 of the Health and Safety Code states:

(a) No person shall obtain or attempt to obtain controlled substances, or procure or attempt to procure the administration of or prescription for controlled substances, (1) by fraud, deceit, misrepresentation, or subterfuge; or (2) by the concealment of a material fact.

	20. Section 1361, Title 16, of the California Code of Regulations states, in relevant part:
:	101
3	(b) Notwithstanding subsection (a), the Board shall use the Uniform Standards
↓	for Substance-Abusing Licensees as provided in section 1361.5, without deviation, for each individual determined to be a substance-abusing licensee.
; ∦	•••
5	21. Section 1361.5, Title 16, of the California Code of Regulations states, in relevant pa
7	(a) If the licensee is to be disciplined for unprofessional conduct involving the use of illegal drugs, the abuse of drugs and/or alcohol, or the use of another prohibited substance as defined herein, the licensee shall be presumed to be a
9	substance-abusing licensee for purposes of section 315 of the [Business and Professions] Code.
0	•••
1	COST RECOVERY
2	22. Section 125.3 of the Code states:
3	(a) Except as otherwise provided by law, in any order issued in resolution of a disciplinary proceeding before any board within the department or before the
4	Osteopathic Medical Board, upon request of the entity bringing the proceeding, the
5	violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.
7	(b) In the case of a disciplined licensee that is a corporation or a partnership, the order may be made against the licensed corporate entity or licensed partnership.
.8	(c) A certified copy of the actual costs, or a good faith estimate of costs where actual costs are not available, signed by the entity bringing the proceeding or its
9	designated representative shall be prima facile evidence of reasonable costs of
20	investigation and prosecution of the date. The date of the hearing, including, but not limited to, charges imposed by the Attorney General.
21	(d) The administrative law judge shall make a proposed finding of the amount
22	of reasonable costs of investigation and prosecution of the case when requested pursuant to subdivision (a). The finding of the administrative law judge with regard to costs shall not be reviewable by the board to increase the cost award. The board may
23	reduce or eliminate the cost award, or remand to the administrative law judge if the proposed decision fails to make a finding on costs requested pursuant to subdivision
24	(a).
25	(e) If an order for recovery of costs is made and timely payment is not made as directed in the board's decision, the board may enforce the order for repayment in any
26	appropriate court. This right of enforcement shall be in addition to any other rights the board may have as to any licensee to pay costs.
27	(f) In any action for recovery of costs, proof of the board's decision shall be conclusive proof of the validity of the order of payment and the terms for payment.
28	Continuative proof of the value of the state

- (g) (1) Except as provided in paragraph (2), the board shall not renew or reinstate the license of any licensee who has failed to pay all of the costs ordered under this section.
- (2) Notwithstanding paragraph (1), the board may, in its discretion, conditionally renew or reinstate for a maximum of one year the license of any licensee who demonstrates financial hardship and who enters into a formal agreement with the board to reimburse the board within that one-year period for the unpaid costs.
- (h) All costs recovered under this section shall be considered a reimbursement for costs incurred and shall be deposited in the fund of the board recovering the costs to be available upon appropriation by the Legislature.
- (i) Nothing in this section shall preclude a board from including the recovery of the costs of investigation and enforcement of a case in any stipulated settlement.
- (j) This section does not apply to any board if a specific statutory provision in that board's licensing act provides for recovery of costs in an administrative disciplinary proceeding.

PERTINENT DRUG INFORMATION

- 23. Opioids are Schedule II controlled substances pursuant to Health and Safety Code section 11055, and are a dangerous drug pursuant to Code section 4022. The Drug Enforcement Administration (DEA) has identified opioids as a drug of abuse. (Drugs of Abuse, DEA Resource Guide (2022 Edition), at pp. 50-51.)
 - (a) Fentanyl is a potent synthetic opioid drug approved for treating severe pain, typically advanced cancer pain. Fentanyl is "approximately 100 times more potent than morphine and 50 times more potent than heroin as an analgesic." (Drugs of Abuse, DEA Resource Guide (2022 Edition), at p. 52.) Fentanyl poses a high risk for addiction and dependence.
 - (b) Hydromorphone is a potent opioid drug used as an analgesic in the management and treatment of moderate to severe acute pain as well as severe chronic pain. Hydromorphone is "approximately two to eight times greater than that of morphine and has a rapid onset of action." (Drugs of Abuse, DEA Resource Guide (2022 Edition), at p. 56.) Hydromorphone poses a high risk for addiction and dependence. (Note: Dilaudid is the brand name for hydromorphone.)
 - (c) Morphine is a potent opioid drug used as an analgesic in the management and treatment of acute or chronic moderate to severe pain. Those dependent on morphine prefer injection because the drug enters the bloodstream more quickly. (Drugs of Abuse, DEA Resource Guide (2022 Edition), at p. 59.) Morphine poses a high risk for addiction and dependence.

- 24. Benzodiazepines are Schedule IV controlled substances pursuant to Health and Safety Code section 11057, and are a dangerous drug pursuant to Code section 4022. The DEA has identified benzodiazepines as a drug of abuse. (Drugs of Abuse, DEA Resource Guide (2022 Edition), at p. 73.)
 - (a) Midazolam is a benzodiazepine and is used to produce sleepiness or drowsiness and relieve anxiety before surgery or certain procedures. When midazolam injection is used before surgery, the patient will not remember some of the details about the procedure. Midazolam injection is also used as an anesthesia to produce loss of consciousness before and during surgery. (Note: Versed is the brand name for midazolam.)
- 25. Propofol is a short acting intravenous anesthetic and is available as a prescription medication for use in human and veterinary medicine. Propofol is used in hospital settings by trained anesthetists for the induction, maintenance of general anesthesia, and sedation of ventilated adults receiving intensive care, for a period of up to 72 hours. Propofol is a prescription medication and is a dangerous drug pursuant to Code section 4022. The DEA has identified propofol as a drug with illicit uses and that it is "mostly abused by health care staff including anesthetists, practitioners, nurses and technicians." "Case reports and surveys published in scientific literature indicate that propofol (commonly referred to as 'milk of amnesia') is abused for recreational purpose, mostly by anesthetists, practitioners, nurses and other health care staff. ... The mortality among anesthesiologists abusing propofol was 28% (7 deaths in 25)."²

FACTUAL ALLEGATIONS

26. Respondent, at all times relevant to the allegations contained in this Accusation, worked as an anesthesiologist at both St. John's Regional Medical Center (SJRMC), located in Oxnard, California, and its sister hospital, St. John's Hospital (SJH), located in Camarillo, California.³

¹ DEA, Diversion Control Division, Drug & Chemical Evaluation Section: Propofol; www.deadiversion.usdoj.gov/drug_chem_info/index.html, (April 2023).

² Ibid.

³ Respondent began working at SJRMC in 2014.

- 27. On or about September 20, 2021, the Board's Central Complaint Unit (CCU) received a letter (dated September 9, 2021) from the president of the medical staff at SJRMC. The letter stated that SJRMC was voluntarily reporting to the Board about an incident involving Respondent that had occurred earlier that year in March 2021. The incident involved Respondent's diversion of "controlled substances intended for patients and used controlled substances while on SJRMC premises," according to the letter. The letter further stated that Respondent had "requested a medical leave of absence immediately after being discovered," which was granted by SJRMC. Significantly, SJRMC's Medical Executive Committee had not conducted a disciplinary investigation into the incident and had no pending recommendation for disciplinary action against Respondent, as of the date of the letter.
- 28. Based upon this letter, CCU initiated an investigation into this incident which the Board later learned had occurred on March 26, 2021.
- 29. On or about March 26, 2021, Respondent was discovered unconscious in the midafternoon inside a hospital staff bathroom located at SJRMC. Hospital staff found Respondent lying unconscious on the bathroom floor in a locked stall. A nurse climbed under the stall's door and unlocked it so that staff could get to Respondent. It appeared that Respondent had fallen and hit her head due to a red mark on her forehead. She was in an altered mental state and totally unaware of what was happening to her when first contacted by staff. Staff then picked Respondent up off of the floor and took her to the Emergency Department (ED) in a wheelchair. Significantly, staff observed an intravenous (IV) port inserted in Respondent's left arm with an "empty" syringe still inserted in the port when they found her in the locked stall.
- 30. On that same date, at approximately 1543 hours, Respondent was admitted to the ED at SJRMC. Upon arrival to the ED, Respondent immediately went to the bathroom alone. Inside the bathroom, Respondent removed the IV port from her arm and discarded it in a trashcan. The ED physician on duty examined Respondent and noticed evidence of recent previous intravenous access in her left arm. The ED physician then went inside the bathroom and found an IV port in a trashcan, which he recognized as hospital property. Respondent later acknowledged to the ED

⁴ Respondent resumed working at SJRMC at the end of August 2022.

physician that she had discarded the IV port in the bathroom. Respondent's blood was also observed on the bathroom floor. Because the ED physician had concerns that Respondent was suicidal, he asked her if he could open her purse. She said "yes." With hospital security present in the ED, Respondent's purse was opened and a mostly empty bottle of fentanyl and a mostly empty bottle of propofol were found. Also found in her purse was an unopened bottle of midazolam. Significantly, the ED physician's final diagnosis of Respondent was that she had "overdosed" on intravenous fentanyl and propofol that day.

- 31. After the drugs were found in her purse, Respondent admitted to self-administering intravenous fentanyl and propofol earlier that day at SJRMC. She also requested a medical leave of absence while still recovering in the ED.
- 32. On that same date, SJRMC's pharmacy director came to the ED and confiscated the drugs that were found in Respondent's purse. The pharmacy director believed that the drugs were obtained from SJRMC because they had the same lot number as the hospital's medication stock. The pharmacy director performed an audit of usage reports from the hospital inventories of both SJRMC and SJH, beginning from in or around January 2021 through March 26, 2021. A review of Respondent's anesthesiology records indicated that she had accessed a number of controlled drugs from the secure medication dispensing systems at both SJRMC and SJH.⁵ The audit report revealed several errors in Respondent's records, and a number of "discrepancies" and "unaccountability" in her use of controlled drugs at both hospitals. Specifically, there were unexplained gaps in how controlled drugs obtained by Respondent were used, which resulted in unaccounted quantities of drugs obtained by Respondent from SJRMC and SJH.
- 33. On or about March 30, 2021, SJRMC notified the DEA regarding Respondent's potential theft of controlled drugs at their facility and SJH.
- 34. On or about April 6, 2021, SJRMC filed a "Report of Theft or Loss of Controlled Substances" with the DEA.⁶ Specifically, SJRMC alerted DEA investigators that Respondent

⁵ Fentanyl, Dilaudid, morphine, and midazolam.

⁶ Upon discovery of a theft or significant loss of controlled drugs, a pharmacy must report the loss in writing to the DEA (Form 106) within one business day.

had diverted: 11.75 ml of fentanyl (100 mcg/2ml vial) and 9.5 ml of midazolam (2 mg/2 ml vial) from SJRMC.

- 35. On or about April 7, 2021, SJRMC filed a second "Report of Theft or Loss of Controlled Substances" with the DEA. SJRMC alerted DEA investigators that Respondent had diverted: 24 ml of fentanyl (100 mcg/2 ml vial), 3.5 ml of midazolam (2 mg/2 ml vial), 26 ml of morphine (5 mg/10 ml vial), and 1 ml of hydromorphone (2 mg/ml vial) from SJH.
- 36. On or about September 9, 2022, during a conversation with a DEA investigator, Respondent admitted to diverting fentanyl, midazolam, and propofol from SJRMC and SJH for illicit personal use. She further admitted that between in or around January 2021 and March 2021, she diverted fentanyl, hydromorphone, morphine, and midazolam on at least 10 separate occasions for illicit personal use.⁷
- 37. On December 13, 2022, Respondent, with her attorney present, voluntarily attended an interview as part of the Board's investigation into the March 26, 2021, incident that occurred at SJRMC, and related allegations involving diversion of controlled drugs. During the interview, Respondent made a number of admissions that are relevant to the allegations and charges brought in this Accusation, including the following:
 - (a) Respondent stated that she was scheduled to work until 3:00 p.m. on March 26, 2021, at SJRMC. Respondent was asked whether she had begun using controlled drugs before or after her shift ended that day, to which she answered, "[t]hat day, I think it was after my shift ended."
 - (b) Respondent stated that she was found unconscious in the bathroom with an IV in her arm, and that she tried to hide it by taking it out.
 - (c) Respondent obtained the fentanyl and propofol she used that day from an anesthesia narcotic box. She also recalled having Versed in her purse that day.

⁷ Following Respondent's admission of stealing controlled drugs from SJRMC and SJH, investigators conducted an administrative audit and discovered that various quantities of fentanyl and midazolam were unaccounted for between in or around October 2020 and December 2020.

- (d) Respondent stated that she "relapsed" in January 2021, when she used fentanyl and Versed. Respondent relapsed again in February, and stated that "it progressively got worse over that month and the following month." She stated that she mainly used fentanyl, propofol, and Versed.
- (e) Between January and March of 2021, Respondent admitted that she had relapsed approximately "10 times." However, she added that previously the DEA had shown her a list of discrepancies causing her to doubt her memory of the actual number of relapses.
- (f) Respondent admitted to using controlled drugs during her shifts between January and March of 2021. On the occasions that she used controlled drugs during shifts, she explained "it would've been if I had a several hour break in between cases."
- (g) Respondent was asked whether she ever treated patients while she was using controlled drugs between January and March of 2021, to which she answered, "[t]here were times when it was probably in my system, yeah."

 Respondent then added "any time you use medication, you're impaired, so, I mean it was probably still in my system."
- (h) Between January and March of 2021, Respondent stated that she was still seeing her psychiatrist, and was also attending "AA meetings" and "PAG meetings."
- (i) Respondent stated that she was currently being investigated by the DEA for the incident that occurred at SJRMC.
- (j) Respondent stated that she has been diagnosed with severe depression and anxiety, and that she has received psychiatric treatment for depression in the past. She also has been diagnosed with severe opioid use disorder, severe alcohol use disorder, and sedative use disorder, and has received inpatient and outpatient treatment for drug dependency in the past.

(k) In or around 2009, Respondent stated that she was arrested by United States Immigration and Customs Enforcement (ICE) agents at the border between the United States and Mexico. Respondent was arrested by ICE for entering the United States while possessing a bottle of Valium with no prescription.⁸ Following the arrest, Respondent stated that she received an infraction and paid a fine.

FIRST CAUSE FOR DISCIPLINE

(Practice of Medicine While Under the Influence of Any Narcotic Drug)

- 38. Respondent has subjected her Physician's and Surgeon's Certificate No. A 78457 to disciplinary action under sections 2227 and 2234, as defined by section 2280 of the Code, in that while practicing medicine she was under the influence of a narcotic drug, as more particularly alleged hereinafter:
 - (a) Paragraphs 26 through 37, above, are hereby incorporated by reference and realleged as if fully set forth herein.

SECOND CAUSE FOR DISCIPLINE

(Use of Controlled Substances and/or Dangerous Drugs to an Extent or in a Manner Dangerous or Injurious to Herself, Others, or the Public)

- 39. Respondent has further subjected her Physician's and Surgeon's Certificate No. A 78457 to disciplinary action under sections 2227 and 2234, as defined by section 2239, subdivision (a), of the Code, in that she used controlled substances and/or dangerous drugs to an extent, or in such a manner as to be dangerous or injurious to herself, another person, or the public, as more particularly alleged hereinafter:
 - (a) Paragraphs 26 through 37, above, are hereby incorporated by reference and realleged as if fully set forth herein.

////

⁸ Respondent stated that she became addicted to Valium when she was in her thirties. Valium is a benzodiazepine and a Schedule IV controlled substance.

SIXTH CAUSE FOR DISCIPLINE

(Violation of State Statutes Regulating Dangerous Drugs or Controlled Substances)

- 43. Respondent has further subjected her Physician's and Surgeon's Certificate No. A 78457 to disciplinary action under sections 2227 and 2234, as defined by section 2238 of the Code, in that she has violated federal and state statutes regulating dangerous drugs or controlled substances, including, but not limited to, Health and Safety Code sections 11170, 11171, 11173, subdivision (a), and 21 U.S.C. section 844, subdivision (a), as more particularly alleged hereinafter:
 - (a) Paragraphs 26 through 37, above, are hereby incorporated by reference and realleged as if fully set forth herein.

SEVENTH CAUSE FOR DISCIPLINE

(Violation of Provisions of the Medical Practice Act)

- 44. Respondent has further subjected her Physician's and Surgeon's Certificate No. A 78457 to disciplinary action under sections 2227 and 2234, as defined by section 2234, subsections (a) and (e), 2238, 2239, subdivision (a), and 2280 of the Code, in that she violated provisions of the Medical Practice Act, as more particularly alleged hereinafter:
 - (a) Paragraphs 26 through 37, above, are hereby incorporated by reference and realleged as if fully set forth herein.

EIGHTH CAUSE FOR DISCIPLINE

(Unprofessional Conduct)

- 45. Respondent has further subjected her Physician's and Surgeon's Certificate No. A 78457 to disciplinary action under sections 2227 and 2234, as defined by section 2234, subsections (a) and (e), 2238, 2239, subdivision (a), and 2280 of the Code, in that she has engaged in conduct which breaches the rules or ethical code of the medical profession, or conduct which is unbecoming to a member in good standing of the medical profession, and which demonstrates an unfitness to practice medicine, as more particularly alleged hereinafter:
 - (a) Paragraphs 26 through 37, above, are hereby incorporated by reference and realleged as if fully set forth herein.

DISCIPLINARY CONSIDERATIONS

- 46. To determine the degree of discipline, if any, to be imposed on Respondent, Complainant alleges:
 - (a) On October 14, 2014, an Interim Order Imposing License Restrictions was issued by the Office of Administrative Hearings in Case No. 800-2013-000730. The Interim Order imposed numerous practice restrictions on Respondent's medical license during the Board's pending investigation into numerous allegations of dangerous misconduct committed by Respondent. The Interim Order issued in Case No. 800-2013-000730 is incorporated by reference as if fully set forth herein.
 - (b) On April 22, 2015, in an action titled *In the Matter of the Accusation Against Mary A. Vreeke*, *M.D.*, in Case No. 800-2013-000730, the Board filed an accusation against Respondent alleging numerous violations of Code sections 2234, 2238, 2239, subdivision (a), 2280, and Health and Safety Code sections 11170, 11171, and 11173, subdivision (a). The allegations of misconduct included Respondent's (i) repeated theft of controlled drugs (fentanyl, morphine, Versed, Valium, and propofol) from locked medication carts while "on duty" as an anesthesiologist at multiple hospitals; (ii) self-administering (intravenously) controlled drugs while "on duty" as an anesthesiologist at multiple hospitals; and (iii) performing anesthesia procedures on patients (epidurals and general sedation) in an impaired condition while "on duty" as an anesthesiologist at multiple hospitals. Accusation No. 800-2013-000730 is incorporated by reference as if fully set forth herein.
 - (c) On May 13, 2016, in Case No. 800-2013-000730, the Board, via stipulated settlement, disciplined Respondent's license and placed it on probation for 7 years pursuant to various terms and conditions. The Board's 2016 Decision and Order is now final and is incorporated by reference as if fully set forth herein.
 - (d) On December 3, 2020, in an action titled In the Matter of the Petition for Reduction of Penalty Against Mary Anne Vreeke, M.D., Case No. 800-2019-